Go or no go? Bristol’s Tyk2 test

September will see an approval decision on one of the year’s biggest expected launches, Bristol’s deucravacitinib. A green light is expected for the oral Tyk2 inhibitor in psoriasis, but whether the project can escape a Jak-like label is less certain.

Meanwhile, several panels are due, including a second for Amylyx’s ALS contender AMX0035. The company comes armed with further data cuts, a strategy also being taken by Oncopeptides, which withdrew its multiple myeloma project Pepaxto last year, then changed its mind. Separately, Ferring’s RBX2660 will be the first microbiome project to come in front of a US panel.